Urinary NMP22 and renal cell carcinoma

Urology

Volumn 55, Issue 2, 2000, Pages 227-230

  Huang, Samuel ^a   Rhee, Eugene ^a   Patel, Hetal ^a   Park, Eunhee ^a   Kaswick, Jon ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR PROTEIN; TUMOR MARKER;

ARTICLE; CELL NUCLEUS MATRIX; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL;

CARCINOMA, RENAL CELL; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 0033979705     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00401-X     Document Type: Article

References (29)

1. Ries LAG, Kosary CK, Hankey BF, et al: SEER Cancer statistics review, 1973-1994. NIH Publication No. 97-2789. Bethesda, National Cancer Institute, 1997, p 223.
2. Parker S.L., Tong T., Bolden S., et al. Cancer statistics, 1997. Cancer J Clin. 47:1997;5-27.
3. Fey E.G., Bangs P., Sparks C., et al. The nuclear matrix defining structural and functional roles. Crit Rev Eukaryot Gene Expr. 1:1991;127-143.
4. Pienta K.J., Getzenberg R.H., Coffey D.S. Cell structure and DNA organization. Crit Rev Eukaryot Gene Expr. 1:1991;355-383.
5. Pienta K.J., Partin A.W., Coffey D.S. Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res. 49:1989;2525-2532.
6. Berezney R., Coffey D.S. Identification of a nuclear protein matrix. Biochem Biophys Res Commun. 60:1991;1410-1417.
7. Getzenberg R.H., Pienta K.J., Huang E.Y.W., et al. Identification of nuclear proteins in the cancer and normal rat prostate. Cancer Res. 51:1991;6514-6520.
8. Fey E.G., Penman S. Nuclear matrix proteins reflect cell type or origin in human cultured cells. Proc Natl Acad Sci USA. 85:1988;121-125.
9. Yang CH, Lambie EJ, and Synder M: NuMA: an unusually long and coiled coil related protein in the mammalian nucleus. J Cell Biol 116: 1303-1317, 1992.
10. Getzenberg R.H., Konety B.R., Oeler T.A., et al. Bladder cancer associated nuclear matrix proteins. Cancer Res. 56:1996;1690-1694.
11. Lakshmanan Y., Subong E.N.P., Partin A.W. Differential nuclear matrix protein expression in prostate cancers correlation with pathological stage. J Urol. 159:1998;1354-1358.
12. Keesee S., Meneghini M.D., Szaro R.P., et al. Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci USA. 91:1994;1913-1916.
13. Konety B.R., Nangia A.K., Nguyen T.T., et al. Identification of nuclear matrix protein alternations associated with renal cell carcinoma. J Urol. 159:1998;1359-1363.
14. Stuurman N., Meijne A.M.L., van der Pool A.J., et al. The nuclear matrix from cells of different origin. J Biol Chem. 265:1990;5460-5465.
15. Lydersen B.K., Pettijohn D.E. Human-specific nuclear protein that associates with the polar region of the mitotic apparatus distribution in a human/hamster hybrid cell. Cell. 22:1996;489-499.
16. Zeng C., He D., Berget S.M., et al. Nuclear mitotic apparatus protein a structural protein interface between the nucleoskeleton and RNA splicing. Proc Natl Acad Sci USA. 91:1999;1505-1509.
17. Zippe C., Pandrangi L., Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol. 161:1999;62-65.
18. Carpinito G.A., Stadler W.M., Briggman J.V., et al. Urinary nuclear matrix protein as a marker for transitional carcinoma of the urinary tract. J Urol. 156:1996;1280-1285.
19. Miyanaga N., Akaza H., Ishikawa S., et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol. 31:1997;162-168.
20. Beahrs OH (Ed): American Joint Committee on Cancer: Manual for Staging of Cancer, 4th ed. Philadelphia, JB Lippincott, 1992, p 201.
21. Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:1982;655-660.
22. Rhee EY, Patel HS, Kurzner P, et al: NMP22: a sensitive urinary tumor marker in the detection of superficial bladder cancer. Presented at the 1998 American Urological Association Meeting, San Diego, California, May 30-June 4, 1998.
23. Soloway M.S., Briggman J.V., Carpinito G.A., et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 156:1996;363-367.
24. Witjes J.A., van der Poel H.G., van Balken M.R., et al. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol. 3:1998;387-391.
25. Sharma S., Zippe C.D., Pandrangi L., et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 162:1999;53-57.
26. Miller T.E., Beausang L.A., Winchell L.F., et al. Detection of nuclear matrix protein in serum from cancer patients. Cancer Res. 52:1992;422-427.
27. Wallace A.C., Nairn R.C. Renal tubular antigens in kidney tumors. Cancer. 29:1972;977-983.
28. Oosterwijik E., Ruiter D.J., Hoedemaeker P.H.J., et al. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinomas and absent from normal kidney. Int J Cancer. 38:1986;489-501.
29. Jayson M., Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma Urology. 51:1998;203-205.